Cargando…
Cholangiocarcinoma: the quest for a second-line systemic treatment
Biliary tract cancers (BTC) are a heterogeneous group of epithelial neoplasms, with a poor prognosis. Advanced BTC remains a challenging, non-curable disease. Gemcitabine plus platinum chemotherapy is the standard of care as first-line (L1) therapy in this setting. Beyond failure of L1, available ev...
Autores principales: | Vienot, Angélique, Neuzillet, Cindy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797902/ https://www.ncbi.nlm.nih.gov/pubmed/35117107 http://dx.doi.org/10.21037/tcr.2018.10.05 |
Ejemplares similares
-
Immune Therapy for Liver Cancers
por: Hilmi, Marc, et al.
Publicado: (2019) -
Patient healthcare trajectories of intrahepatic cholangiocarcinoma in France: A nationwide retrospective analysis
por: Neuzillet, Cindy, et al.
Publicado: (2022) -
Second-Line Chemotherapy for Intrahepatic Cholangiocarcinomas: What Is the Real Gain?
por: Garajová, Ingrid, et al.
Publicado: (2023) -
Pattern of progression of intrahepatic cholangiocarcinoma: Implications for second‐line clinical trials
por: Tovoli, Francesco, et al.
Publicado: (2021) -
Chordoma: The Quest for Better Treatment Options
por: Heery, Christopher R.
Publicado: (2016)